The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IWWM-12 2024 | Ibrutinib plus rituximab in symptomatic Japanese patients with Waldenström’s macroglobulinemia
Naohiro Sekiguchi, MD, PhD, National Hospital Organization Disaster Medical Center, Tachikawa, Japan, discusses a study investigating ibrutinib plus rituximab in symptomatic patients with Waldenström’s macroglobulinemia in Japan. Positive findings from this study supported the approval of this combination in Japan. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Janssen, Ono; Research funding: Incyte Biosciences Japan, Janssen, Mitsubishi Tanabe Pharma Corporation, MSD, Ono.
